Trial Profile

TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
Indications Carcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Biomarker; Therapeutic Use
Acronyms TWICE-IRI

19 Oct 2023 Planned End Date changed from 1 Aug 2023 to 1 Jun 2024.
19 Oct 2023 Status changed from recruiting to active, no longer recruiting.
10 Sep 2020 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com